We are committed to
advancing improved
treatments for patients
with cancer.
Board of Directors
Patricia L. Allen

Ms. Allen, joined Zafgen as Chief Financial Officer in January 2013. She offers over 20 years of financial leadership experience in the biotechnology industry at both publicly traded and private companies. Ms. Allen serves as the Chair of the Audit Committee of the Deciphera Board of Managers.

Previously, Ms. Allen served as the Vice President of Finance, Treasurer and Principal Financial Officer of Alnylam Pharmaceuticals, where she had significant interactions with the investment community and was influential in raising over $900 million between 2004 and 2011 via the Company’s initial public offering, follow-on common stock offerings and multiple business development transactions with top-tier pharmaceutical companies, including Novartis, Roche and Takeda Pharmaceuticals. Ms. Allen also served as the Corporate Controller and eventually the Director of Finance at Alkermes, Inc. where she spent 12 years. Ms. Allen began her career as an auditor at Deloitte & Touche, LLP. Ms. Allen graduated Summa Cum Laude from Bryant College with a B.S. in Business Administration.

Read More
Edward J. Benz, Jr., M.D.

Edward J. Benz, Jr., M.D. is President and Chief Executive Officer Emeritus of the Dana-Farber Cancer Institute, which he led from 2000-2016. Dr. Benz is also the Richard and Susan Smith Distinguished Professor of Medicine and Professor of Pediatrics and Genetics at Harvard Medical School.

Immediately prior to assuming the presidency at Dana-Farber, Dr. Benz was chairman of the Department of Medicine at the Johns Hopkins University School of Medicine and the Sir William Osler Professor of Medicine. He received a bachelor’s degree, cum laude, from Princeton University, a medical degree, magna cum laude, from Harvard Medical School, and a master’s degree (privatum) from Yale University. Author of more than 300 articles, books, chapters, reviews, and abstracts, Dr. Benz is a past president of both the American Society of Hematology and the American Society of Clinical Investigation, and was an associate editor of the New England Journal of Medicine from 2002-2016.

Read More
James A. Bristol, Ph.D.

James A. Bristol, Ph.D. is Chairman of the Deciphera Board of Managers. Dr. Bristol was previously Senior Vice President, Worldwide Discovery Research with Pfizer. Prior to this position, he was Vice President, Discovery Research, at the Pfizer Global Research & Development site in Ann Arbor, Michigan, and Vice President, Discovery Research with the Parke-Davis Pharmaceutical Research Division of Warner-Lambert.

Dr. Bristol has served on the Gordon Research Conferences Board of Trustees and was National Chairman of the Medicinal Chemistry division in the American Chemical Society Division in 1995. Dr. Bristol has 46 publications in peer-reviewed journals and 30 granted U.S. patents. In recognition of his service to the pharmaceutical industry, Dr. Bristol received the American Chemical Society’s Earle B. Barnes Award for Leadership in Chemical Research Management in 2004.

Read More
John Martin

John Martin is the CEO and President of Clinical Reference Laboratory. He previously served as Executive Vice President and Chief Administrative Officer of CRL. Prior to CRL, Mr. Martin held senior executive roles with Viracor-IBT Laboratories, a clinical diagnostic laboratory specializing in infectious disease and immunology.

Mr. Martin initially served as Chief Financial Officer and then as President and CEO of Viracor-IBT. Prior to Viracor, Mr. Martin was with George K. Baum & Company, where he served as Managing Director leading the firm’s middle market investment banking and strategic advisory practice. Mr. Martin’s career also includes 11 years with Fortune 100 companies, including senior management roles with Sprint Corporation and financial management roles with General Electric and GE Capital. Mr. Martin holds a B.S. in Finance from Kansas State University.

Read More
Liam Ratcliffe, M.D., Ph.D.

Liam Ratcliffe, M.D., Ph.D. is a Managing Director at New Leaf Venture Partners, and concentrates on biopharmaceutical investing. Liam joined New Leaf in September 2008. He is currently on the board of directors of Afferent Pharmaceuticals Inc., Calchan Holdings Ltd., Karus Therapeutics and UNUM Therapeutics.

Liam previously served as Senior Vice President and Development Head for Pfizer Neuroscience, as well as Worldwide Head of Clinical Research and Development. Liam began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa. He received his M.D. degree and Ph.D. degree in immunology from the University of Cape Town and his M.B.A. degree from the University of Michigan. Liam completed his internal medicine training and fellowship in Immunology at Groote Schuur Hospital and associated teaching hospitals in Cape Town, South Africa.

Read More
Michael Ross, Ph.D.

Michael Ross, Ph.D. joined SV Life Sciences as a Venture Partner in 2001 and became a Managing Partner in 2002. He also serves on the board of overseers at the Thayer School of Engineering (Dartmouth College).

Prior to joining SV Life Sciences, Dr. Ross was the tenth employee at Genentech where he worked for 13 years. He served as Genentech team leader for Humulin® (human insulin-Lilly), Roferon® (Interferon alpha -Roche), Protropin® (hGH), and as Vice President of Development during the development of Activase®, Nutropin® and Pulmozyme®. Dr. Ross then started Genentech’s protein and antibody engineering and small molecule discovery effort as Vice President of Medicinal and Biomolecular Chemistry. He was the Founding CEO of Arris Pharmaceutical (now part of Quest), MetaXen (now part of Exelixis), ExSAR and CyThera (now part of Viacyte). Dr. Ross received his A.B. in chemistry from Dartmouth, his Ph.D. in Chemistry at Caltech, and held an NIH postdoctoral fellowship in Molecular Biology at Harvard.

Read More
Michael D. Taylor, Ph.D.

Michael D. Taylor, Ph.D. is President and CEO of Deciphera Pharmaceuticals. Prior to Deciphera, Mike was CEO of Ensemble Therapeutics where he completed seven Research Alliances.

Mike holds a Ph.D. in Medicinal Chemistry from the State University of New York at Buffalo School of Pharmacy and was awarded an NIH postdoctoral fellowship in natural products synthesis and structure elucidation at the University of Pennsylvania. He also attended the University of Michigan MBA program. Mike has authored or coauthored 65 manuscripts and published abstracts and is co-inventor on 8 patents.

Read More
Dennis Walsh, CPA.

Dennis Walsh, CPA. is a partner with Walsh Washburn, LLC which he helped found in 2003. He advises a wide variety of clients in financial and tax matters. Prior to this he was the controller and tax director for six years for Americo Life, a privately owned life insurance company.

Mr. Walsh began his career with Touch Ross & Company (now Deloitte) where he served in the tax department for ten years. Mr. Walsh holds a Masters in Accounting from the University of Missouri, Kansas City as well as a BSBA in Accounting from Rockhurst University, and is a licensed Certified Public Accountant.

Read More
Back to Top